Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599084 | 0.84 | CES2 (0.45) | CES2CES1BCHERIPK1ALDH1A1 | |
| SCHEMBL29718813 | 0.84 | CES2 (0.45) | CES2CES1BCHERIPK1ALDH1A1 | |
| SCHEMBL6666485 | 0.83 | CES2 (0.48) | CES2CES1BCHERIPK1ALDH1A1 | |
| SCHEMBL1124265 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ALOX15CXCL8MEN1KMT2A | |
| SCHEMBL30098315 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ALOX15CXCL8MEN1KMT2A | |
| SCHEMBL24977211 | 0.82 | ANO1 (0.41) | CES2CES1BCHEALDH1A1ALOX15 | |
| SCHEMBL5419671 | 0.82 | CES2 (0.43) | CES2CES1RIPK1DPP4 | |
| SCHEMBL6967661 | 0.82 | CES2 (0.47) | CES2CES1BCHERIPK1ALDH1A1 | |
| SCHEMBL723768 | 0.82 | CXCL8 (0.56) | CES2CES1BCHERIPK1CXCL8 | |
| SCHEMBL4877644 | 0.81 | CA12 (0.33) | ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220267337-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| CN-108707114-B | Acetamide compound and preparation method and application thereof | 上海泰禾国际贸易有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-108452848-B | Catalyst | 上海兰立生物科技有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-9518222-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-13 | — | — | US | disclosed |
| US-9518222-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-13 | — | — | US | disclosed |
| US-20160046864-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-02-18 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1664043-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050133762-A1 | Liquid crystalline compound having high optical anisotropy and liquid crystalline composition comprising the same | SAMSUNG ELECTRONIC CO., LTD. (KR) | 2005-06-23 | — | — | US | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | PDK1, PDK2, PDK3 | CES2 4663/4885CES1 3759/4885BCHE 4709/4885 |
| US-20220267337-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | CES2 4622/4885CES1 3293/4885BCHE 4545/4885 |
| US-20160046864-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD1, YBX1, LEF1 | CES2 1440/4885CES1 982/4885BCHE 2329/4885 |
| US-20050133762-A1 | Liquid crystalline compound having high optical anisotropy and liquid crystalline composition comprising the same | KIF23, CDK13, KIF11 | CES2 4798/4885CES1 3965/4885BCHE 2723/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | CES2 4622/4885CES1 3293/4885BCHE 4545/4885 |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | CES2 3484/4885CES1 2889/4885BCHE 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.